Brain: Frontotemporal atrophy

QUIBIM

Source: https://quibim.com/
QUIBIM has developed an automatic analysis method to quantify the volume of both left and right frontal and temporal lobes as well as left and right hippocampus to assess disease diagnosis and progression.
Product specifications Information source: Vendor
Last updated: March 10, 2020
General
Product name Brain: Frontotemporal atrophy
Company QUIBIM
Subspeciality Neuro
Modality MR
Disease targeted Brain atrophy, Alzheimer's, Frontotemporal dementia
Key-features Absolute and relative volume
Suggested use Without interference of a radiologist: AI-only diagnosis
Data characteristics
Population Patients with neurological degenerative disease
Input MRI T1 GRE 3D T1 Fast Gradient Echo
Input format
Output One-page structured report: 3D brain parcellation render, lobe segmentation, table with volume statistics, normative bars of volume
Output format DICOM Secondary Capture / PDF
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition
Processing time > 10 minutes
Certification
CE Certified, Class IIa
FDA No or not yet
Market presence
On market since 01-2019
Distribution channels
Countries present (clinical, non-research use) 6
Paying clinical customers (institutes) 5+
Research/test users (institutes)
Pricing
Pricing model Pay-per-use, Subscription, License
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers